Details:

Alternative Title:
Vaccine
Publisher's site:
http://dxdoiorg/101016/jvaccine201302048
Personal Author:
Raczniak, Gregory A ; Thomas, Timothy K ; Bulkow, Lisa R ; Negus, Susan E ; Zanis, Carolyn L ; ... More +
Raczniak, Gregory A ; Thomas, Timothy K ; Bulkow, Lisa R ; Negus, Susan E ; Zanis, Carolyn L ; Bruce, Michael G ; Spradling, Philip R ; Teshale, Eyasu H ; McMahon, Brian J Less -
Description:
Background

Hepatitis A is mostly a self-limiting disease but causes substantial economic burden Consequently, United States Advisory Committee for Immunization Practices recommends inactivated hepatitis A vaccination for all children beginning at age 1 year and for high risk adults The hepatitis A vaccine is highly effective but the duration of protection is unknown

Methods

We examined the proportion of children with protective hepatitis A antibody levels (anti-HAV ≥20 mIU/mL) as well as the geometric mean concentration (GMC) of anti-HAV in a cross sectional convenience sample of individuals aged 12–24 years, who had been vaccinated with a two-dose schedule in childhood, with the initial dose at least 5 years ago We compared a subset of data from persons vaccinated with two-doses (720 ELU) at age 3–6 years with a demographically similar prospective cohort that received a three-dose (360 ELU) schedule and have been followed for 17 years

Results

No significant differences were observed when comparing GMC between the two cohorts at 10 (P = 0467), 12 (P = 0496), and 14 (P = 0175) years post-immunization For the three-dose cohort, protective antibody levels remain for 17 years and have leveled-off over the past 7 years

Conclusion

The two- and three-dose schedules provide similar protection >14 years after vaccination, indicating a booster dose is not needed at this time Plateauing anti-HAV GMC levels suggest protective antibody levels may persist long-term


Subjects:
[+]
Adolescent Article Child Child, Preschool Cohort Studies Female Follow-Up Studies Hepatitis A Hepatitis A Antibodies Hepatitis A Vaccines Humans Immunization Schedule Male Prospective Studies Time Factors Vaccination Vaccines, Inactivated Young Adult
Source:
Vaccine 31(17):2152-2155
Pubmed ID:
23470239
Pubmed Central ID:
PMC4648811
Document Type:
Journal Article
Funding:
CC999999/Intramural CDC HHS/United States ; U01PS001097/PS/NCHHSTP CDC HHS/United States ; U50/CCU022279/PHS HHS/United States
CC999999/Intramural CDC HHS/United States ; U01PS001097/PS/NCHHSTP CDC HHS/United States ; U50/CCU022279/PHS HHS/United States Less -
Place as Subject:
United States
Location:
United States
Collection(s):
CDC Public Access
Main Document Checksum:
[+]
urn:sha256:97400df5982a006923395ee5c2646148b5a9cc8ca3869843a664685237a9f864
Download URL:
https://stacks.cdc.gov/view/cdc/36501/cdc_36501_DS1.pdf
File Type:

Supporting Files

• nihms736937.nxml

  bin

More +